Using Facebook For Good
…Australia. Originally from the central valley in California, Stephanie lost her brother, Tony, to melanoma in 2019. Tony was an…
Using Facebook For Good
…Australia. Originally from the central valley in California, Stephanie lost her brother, Tony, to melanoma in 2019. Tony was an…
,
A Letter From Our Vice President | January 2023
…at Melanoma as an official “Give with Confidence” charity due to our strong financial health, ongoing accountability, and transparency, and…
,
Iovance Biotherapeutics Announces Approval for TIL Therapy
…in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melanoma. The trial is enrolling participants with…
,
,
May is Brain Tumor Awareness Month
…to forget even hearing the words “brain metastases.” An estimated 7% to 10% of patients with melanoma develop brain metastases. These…
Book Suggestions for Caregivers
Supporting a loved one with melanoma can be a daunting journey. It often feels overwhelming. You are not only taking…
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
…of tumor cell death, and the activation of a systemic anti-tumor immune response. About Advanced Melanoma Melanoma is the fifth…
,
How Melanoma Cured Dylan Slattery
…called, he was told he had melanoma – a lethal form of skin cancer. Dylan emerged from surgery with a…
,
Immunocore’s Tebentafusp Successfully Activates T Cells Against Uveal Melanoma
…Drug Administration (FDA) and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme. Uveal melanoma is…
,
,
Melanoma Survivor on Her Way To Princeton With Her Sights Set for the U.S. Olympic Team
…back and continuing to share her story. She’s chosen to partner with AIM at Melanoma for her senior project and…
,
Jim Zeoli Had Never Spent Much Time Thinking About Melanoma—Until He Was Diagnosed
by Mara Klecker Jim Zeoli had never spent much time thinking about melanoma before his own diagnosis at the end…
,
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026